Zura Bio Q3 net income $25.825 million negative
ZURA•Zura Bio reported Q3 net income of negative $25.825 million and EPS of negative $0.20. Cash and cash equivalents totaled $187.70 million as of Sept. 30, 2026, funding operations through 2028.
1. Quarterly results
Zura Bio reported a Q3 pretax loss of $27.046 million and an operating loss of $28.773 million, with operating expenses of $28.773 million. EPS was negative $0.20.
2. Cash position
Cash and cash equivalents were $187.70 million as of Sept. 30, 2026, which the company said funds operations through 2028.
